About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Discovery Sheds Light on Liver Cancer Treatment

by Sheela Philomena on March 24, 2011 at 1:05 PM
Font : A-A+

 New Discovery Sheds Light on Liver Cancer Treatment

Researchers have identified a new mechanism in gene regulation behind the development of a form of liver cancer called hepatocellular carcinoma (HCC). This finding would open new avenues in lung cancer treatment, say researchers.

In the journal Hepatology, Devanand Sarkar, M.B.B.S., Ph.D., Harrison Endowed Scholar in Cancer Research at VCU Massey Cancer Center, a Blick scholar and assistant professor in the Department of Human and Molecular Genetics and a member of the VIMM at VCU School of Medicine, describes for the first time how RNA-induced silencing complex (RISC) contributes to the development of liver cancer.

Advertisement

RISC is an important factor in post-transcriptional gene regulation, which occurs between transcription (where DNA is converted to RNA) and translation (where RNA is converted to protein). These processes regulate functions such as cellular growth, division and death. Sarkar and his team identified the proteins AEG-1 and SND1 as factors that increase RISC activity and lead to the development of liver cancer.

For years, Sarkar has been studying the role of AEG-1 in cancer with his collaborator on this research, Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair in Cancer Research at VCU Massey, professor and chair of the Department of Human and Molecular Genetics and director of the VIMM.
Advertisement

"AEG-1 works as a scaffold protein," says Sarkar. "If you think about scaffolding outside of a biological setting, its function is to help facilitate things like construction. In this case, AEG-1 was found to work with another protein, SND1, to provide the scaffold for the formation of RISC. Since both AEG-1 and SND1 are increased in HCC, the net effect is increased RISC activity."

The study clearly identifies SND1 as a novel regulator of liver cancer. As SND1 is a molecule that can be inhibited by drugs, Sarkar's findings open up a novel avenue for treating liver cancer by targeting SND1.

"RISC works by degrading tumor-suppressor mRNAs, which transmit genetic information in a cell that prevents the formation of tumors. This allows other cancer-causing factors to go unchecked and aid tumor growth," says Sarkar. "Since we've shown that RISC activity is higher in cancer cells than normal, healthy cells, we're hopeful that inhibiting SND1 to decrease RISC activity will do little, if any, damage to healthy liver cells while stopping cancer progression."

Sarkar's team is working hard to find the most clinically-relevant SND1 inhibitors. Once these are found, the researchers will need to prove their effectiveness in several more experiments. The ultimate goal is to move these findings to Phase I clinical trials for patients with liver cancer.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Macronutrients Calculator for Weight Loss
Quiz on Kidney
World Disability Day 2022 - The Role of Innovative Transformation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alcoholic Liver Disease Hepatitis A Hepatitis B Liver Cancer Cancer and Homeopathy Neonatal Jaundice Bubbles and Brews - Alcohol Facts Cancer Facts Cancer Tattoos A Body Art 

Most Popular on Medindia

Drug - Food Interactions Blood Pressure Calculator Loram (2 mg) (Lorazepam) Pregnancy Confirmation Calculator Noscaphene (Noscapine) Nutam (400mg) (Piracetam) Daily Calorie Requirements Sinopril (2mg) (Lacidipine) Vent Forte (Theophylline) Diaphragmatic Hernia
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Discovery Sheds Light on Liver Cancer Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests